The role of PPARs in the transcriptional control of cellular processes

Drug News and Perspectives

Volumn 15, Issue 3, 2002, Pages 147-154

  Guan, Youfei ^a   Zhang, Yahua ^a   Breyer, Matthew D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; ISOPROTEIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CELL DIFFERENTIATION; CELL METABOLISM; CONTROLLED STUDY; ENERGY BALANCE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION;

EID: 0036274972     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.3.840011     Document Type: Review

References (88)

1. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions
2. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
3. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptor
4. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
5. The nuclear receptor ligand-binding domain: Structure and function
6. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
7. Peroxisome proliferator-activated receptors in the cardiovascular system
8. Activation of PPARdelta alters lipid metabolism in db/db mice
9. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
10. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
11. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
12. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
13. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse
14. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes
15. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
16. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein as a coactivator for PPAR
17. A corepressor and chicken ovalbumin upstream promoter transcriptional factor proteins modulate peroxisome proliferator-activated receptor-gamma2/retinoid X receptor alpha-activated transcription from the murine lipoprotein lipase promoter
18. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors
19. Lipid metabolism: Peroxisome-proliferator-activated receptors and the regulation of genes of lipid metabolism
20. Peroxisome proliferator-activated receptor: Nuclear control of metabolism
21. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation
22. Mechanism of action of fibrates on lipid and lipoprotein metabolism
23. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice
24. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)
25. The PPARalpha-leukotriene B4 pathway to inflammation control
26. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia
27. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
28. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
29. Expression of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary cultures of human vascular endothelial cells
30. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not PPARgamma activators
31. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
32. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis
33. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
34. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
35. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta
36. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
37. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice
38. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
39. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-El preosteoblasts
40. Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts
41. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
42. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
43. A nuclear receptor to prevent colon cancer
44. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
45. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling
46. Mechanisms by which thiazolidinediones enhance insulin action
47. The nuclear receptor PPARgamma: Bigger than fat
48. PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer
49. Peroxisome proliferator-activated receptors: Roles in tumorigenesis and chemoprevention in human cancer
50. PPARgamma: An essential regulator of adipogenesis and modulator of fat cell function
51. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis
52. Differential activation of adipogenesis by multiple PPAR isoforms
53. A dominant-negative peroxisome proliferator-activated receptor gamma (PPAR-gamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis
54. PPARgamma is required for placental, cardiac, and adipose tissue development
55. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
56. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
57. A Prol2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
58. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
59. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death
60. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma
61. Differentiation and reversal of malignant change in colon cancer through PPAR-gamma
62. Peroxisome proliferator-activated receptor gammal (PPARgammal) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation
63. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, pl8(INK4c) and p21(Wafl/Cipl), during adipogenesis
64. PPARgamma agonists inhibit production of monocyte inflammatory cytokines
65. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
66. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation
67. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
68. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis
69. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
70. A PPAR gamma-LXR-ABCAI pathway in macrophages is involved in cholesterol efflux and atherogenesis
71. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAI pathway
72. Inhibition of oxidalion of low density lipoprotein by troglitazone
73. Peroxisome proliferator-activated receptor gamma ligands inhibit development of ather-osclerosis in LDL receptor-deficient mice
74. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice
75. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
76. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
77. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
78. The mechanisms by which both heterozygous PPARgamma deficiency and PPARgamma agonist improve insulin resistance
79. The fat-derived hormone adiponectin reverses insulin resistance associaled with both lipoatrophy and obesity
80. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes
81. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
82. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
83. You are what you secrete
84. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
85. The hormone resistin links obesity to diabetes
86. PPAR gamma is required for placental, cardiac, and adipose tissue development
87. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
88. PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance